Literature DB >> 19076366

Human mast cells stimulate activated T cells: implications for multiple sclerosis.

Theoharis C Theoharides1, Duraisamy Kempuraj, Taxiarchis Kourelis, Akrivi Manola.   

Abstract

Multiple sclerosis is an autoimmune demyelinating disease of the central nervous system mainly mediated by Th1 and/or Th17 cells, which cross the blood-brain barrier. Recent evidence indicates that Th2 cells and mast cells, typically associated with allergic reactions, are also involved. Brain mast cells are critically located perivascularly and secrete numerous proinflammatory and vasoactive molecules that can disrupt the blood-brain barrier, a finding that precedes clinical or pathologic signs of multiple sclerosis. Brain mast cells in multiple sclerosis are activated by neural factors, including substance P, myelin basic protein, and corticotropin-releasing hormone, caused by acute stress, which induce release of several inflammatory mediators. Mast cells can stimulate activated T cells coming in contact with them at the blood-brain barrier, as well as after stimulation with myelin basic protein or substance P. Pretreatment with the flavone luteolin blocks mast cell stimulation and T cell activation, as well as experimental autoimmune encephalitis. Interactions between mast cells and T cells could constitute a new and unique therapeutic target for multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076366     DOI: 10.1196/annals.1418.029

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

Review 1.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

2.  Stress and multiple sclerosis: what's new?

Authors:  Julián Benito-León
Journal:  Neuroepidemiology       Date:  2011-02-17       Impact factor: 3.282

Review 3.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Authors:  George P Christophi; Ross C Gruber; Michael Panos; Rebecca L Christophi; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2011-12-02       Impact factor: 3.969

Review 5.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

6.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

7.  The levels of blood mercury and inflammatory-related neuropeptides in the serum are correlated in children with autism spectrum disorder.

Authors:  Gehan Ahmed Mostafa; Geir Bjørklund; Mauricio A Urbina; Laila Yousef Al-Ayadhi
Journal:  Metab Brain Dis       Date:  2016-01-06       Impact factor: 3.584

Review 8.  The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.

Authors:  Abbas Mirshafiey; Babak Asghari; Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Gholamreza Azizi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

Review 9.  Mast cells: an expanding pathophysiological role from allergy to other disorders.

Authors:  Preet Anand; Baldev Singh; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-06       Impact factor: 3.000

10.  Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta.

Authors:  Zohara Sternberg; Kailash Chadha; Alicia Lieberman; Allison Drake; David Hojnacki; Bianca Weinstock-Guttman; Frederick Munschauer
Journal:  J Neuroinflammation       Date:  2009-10-13       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.